Founded in 2006 by Dr. M. Romero-Ramos, the CNS Disease Modelling Group explores the mechanisms behind neurodegeneration, with a special focus on Parkinson’s disease and other alpha-synucleinopathies.

Our Research

We use a broad spectrum of disease models, including:

• Neurotoxin-based and transgenic models (classical mouse lines and viral vector–mediated transgenesis)
• Alpha-synuclein fibril templation based models, one of the latest approaches in the field

Our recent work investigates how the overexpression and/or aggregation of alpha-synuclein set off cellular and molecular changes that drive disease progression.

Focus Areas

Integrating insights from rodent models, patient-derived biosamples, and cell culture systems we aim to elucidate

• Early and progressive changes in neurons with significance in the disease presentation
• The role of the immune system—both local and peripheral—in neuronal survival
• Novel therapeutic strategies targeting both neuronal and immune pathways 

Our Goal

We aim to identify novel biomarkers and therapeutic targets that can lead to disease-modifying treatments, offering new hope to patients with neurodegenerative disorders.

Leadership & Affiliations

• Dr. M. Romero-Ramos – Group Leader, Lundbeck Foundation Parkinson Disease Center (PACE)
• Affiliated Researcher, DANDRITE (Danish Research Institute of Translational Neuroscience), part of the Nordic EMBL Partnership for Molecular Medicine
• Our lab is part of the NeuroCampus Aarhus.community